There is no single best treatment for ankylosing spondylitis. The most effective approach combines consistent exercise with medication tailored to your level of disease activity. For many people, anti-inflammatory drugs are enough to control symptoms. For others, biologic injections or newer oral medications can dramatically reduce pain, stiffness, and the progression of spinal fusion. The “best” treatment is the one that gets your disease activity score low enough to protect your spine and let you live normally.
NSAIDs Are the Starting Point
Nonsteroidal anti-inflammatory drugs are the first-line treatment for ankylosing spondylitis and remain the backbone of therapy for many patients. These aren’t just painkillers in this context. Taken consistently, they reduce the inflammation that drives spinal damage. Some people with mild to moderate disease can manage well on NSAIDs alone for years.
The key is taking them regularly rather than only when pain flares. If two different NSAIDs at full dose over a combined period of about four weeks don’t bring your symptoms under control, you move to the next tier of treatment.
Biologic Medications for Active Disease
When NSAIDs aren’t enough, biologic medications are the standard next step. These are injectable drugs that target specific parts of the immune system driving your inflammation. There are two main classes used in ankylosing spondylitis, and both work well for most people.
TNF Inhibitors
Drugs that block tumor necrosis factor (TNF), a protein that fuels inflammation, have been used for ankylosing spondylitis for over two decades. They are typically the first biologic prescribed. Options include adalimumab (given as a subcutaneous injection every two weeks), etanercept (once weekly), golimumab (every four to eight weeks after loading), and others. Most people notice significant improvement within the first three months.
IL-17 Inhibitors
A newer class targets interleukin-17, a different inflammatory protein. Secukinumab and ixekizumab both fall into this category. Secukinumab is given at a dose of 150 mg by injection, sometimes with an initial loading phase. Ixekizumab is given at 80 mg, either every two or every four weeks depending on the phase of treatment. Head-to-head registry data show that TNF inhibitors and IL-17 inhibitors produce similar response rates, so the choice often comes down to your doctor’s assessment of your specific situation and any other conditions you have.
What Happens When a Biologic Stops Working
Not everyone responds to their first biologic, and some people respond initially but lose effectiveness over time. These are known as primary and secondary non-response. Primary non-response means you never improved meaningfully after at least three months on the drug. Secondary non-response means the drug worked for a while, then your symptoms flared back.
Current guidelines recommend re-evaluating the diagnosis first, then switching to a different biologic. You can either try a second TNF inhibitor or switch to an IL-17 inhibitor. A major ongoing clinical trial (ROC-SpA) is comparing these two strategies directly, but for now, both are considered reasonable options. If one class hasn’t worked, switching to the other mechanism is a logical move.
JAK Inhibitors: A Newer Oral Option
For people who haven’t responded to or can’t tolerate TNF inhibitors, upadacitinib (brand name Rinvoq) offers something different: a daily pill instead of an injection. It’s a JAK inhibitor, meaning it blocks a signaling pathway inside immune cells rather than targeting a single protein outside the cell. At 15 mg once daily, it has shown marked improvement in disease activity, physical function, and spinal inflammation visible on MRI.
There’s an important trade-off. Upadacitinib carries a boxed warning from the FDA for increased risks of serious infections, blood clots, cardiovascular events, and certain cancers. These warnings come partly from safety data on JAK inhibitors in rheumatoid arthritis, where the risks were higher compared to TNF inhibitors. This is why upadacitinib is approved only for people who have already tried and failed a TNF blocker, not as a first-choice biologic.
How to Know if Treatment Is Working
Doctors track ankylosing spondylitis with standardized scores. The two most common are the BASDAI (a questionnaire you fill out rating your symptoms on a 0-to-10 scale) and the ASDAS (which combines your symptom scores with a blood inflammation marker). A BASDAI below 4 generally signals acceptable disease control. An ASDAS below 1.3 means inactive disease, which is the target.
In practice, about 47% of patients in active treatment achieve a BASDAI under 4, but only about 19% reach the stricter threshold of inactive disease on the ASDAS. This means most people experience significant improvement, but truly quiet disease is harder to achieve. Your treatment plan should aim for the lowest disease activity score you can sustain, recognizing that “good enough” control still protects your spine from further damage.
Exercise Is Not Optional
Physical therapy and daily exercise are as important as any medication for ankylosing spondylitis. This isn’t generic advice to “stay active.” Specific exercise programs targeting spinal mobility, chest expansion, and shortened muscle groups have been shown to significantly improve both spinal movement and physical function scores.
A randomized trial comparing two approaches found that a method called Global Posture Reeducation, which stretches and strengthens the muscle chains that tighten as the spine stiffens, produced greater improvements than conventional exercises alone. The GPR group improved significantly across nearly all measures of spinal mobility and daily function. Conventional exercises (cervical, thoracic, and lumbar flexibility work plus chest expansion) also helped, just not as much.
The practical takeaway: a structured program designed specifically for ankylosing spondylitis, ideally with a physiotherapist who understands the condition, delivers better results than general stretching. Consistency matters more than intensity. Daily movement, even 15 to 20 minutes, helps maintain the range of motion that medication alone cannot fully preserve.
When Surgery Becomes Necessary
Surgery is reserved for people with severe spinal deformity that affects their ability to look forward, breathe comfortably, or function. The main indication is fixed kyphosis, where the upper spine curves forward so much that you can’t stand upright. Surgeons measure this using the distance your spine’s center of gravity falls ahead of your pelvis.
For moderate imbalance (6 to 8 cm forward shift), a procedure that opens wedges in the back of the spine can correct the curve. For severe imbalance (greater than 12 cm) with a sharp angular deformity, a more aggressive technique removes a wedge of bone from a single vertebra to straighten the spine in one segment. When the kyphosis exceeds 40 degrees with significant side-to-side imbalance, surgeons may need to remove an entire vertebral segment. These are complex, high-risk operations performed only when deformity is disabling and conservative treatment has been maximized.
One challenge specific to ankylosing spondylitis is that the ligaments and disc spaces in the front of the spine can calcify or turn to bone, making certain techniques difficult or impossible. This is why surgical planning for AS requires imaging that maps exactly where fusion has occurred.
Putting a Treatment Plan Together
The most effective treatment for ankylosing spondylitis layers multiple approaches. NSAIDs for baseline inflammation control, a biologic or JAK inhibitor if disease activity remains high, and a daily exercise routine to maintain mobility and posture. Smoking cessation matters too, as smoking accelerates spinal fusion and reduces how well biologics work.
Treatment typically evolves over time. You might start with NSAIDs and exercise, add a TNF inhibitor if your ASDAS stays above target, and switch to an IL-17 inhibitor or upadacitinib if the first biologic fails. The goal at every stage is the same: get inflammation as low as possible, keep your spine moving, and prevent the irreversible fusion that defines advanced disease.